Mirum Pharmaceuticals MIRM
Mirum Pharmaceuticals, Inc. · Nasdaq · Pharmaceutical Preparations
$85.81+0.29%close on Oct. 28, 2026 · volume 535K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 14, 2026 | Eric Bjerkholt CHIEF FINANCIAL OFFICER | Sold | 9,943 | $98.37 | $978,093 |
| Sept. 2, 2026 | Jolanda Howe SVP, GLOBAL CONTROLLER | Sold 10b5-1 plan | 658 | $100.00 | $65,800 |
| Sept. 1, 2026 | Christopher Peetz CHIEF EXECUTIVE OFFICER, director | Sold 10b5-1 plan | 30,000 | $98.68 $98.08-$98.91 | $2.96 million |
| Aug. 18, 2026 | Jolanda Howe SVP, GLOBAL CONTROLLER | Sold | 40,000 | $100.00 | $4.00 million |
| Aug. 11, 2026 | Eric Bjerkholt CHIEF FINANCIAL OFFICER | Sold 10b5-1 plan | 6,001 | $99.90 | $599,510 |
| Aug. 10, 2026 | Christopher Peetz CHIEF EXECUTIVE OFFICER, director | Sold 10b5-1 plan | 20,000 | $98.92 $98.51-$100.14 | $1.98 million |
| Aug. 3, 2026 | Jolanda Howe SVP, GLOBAL CONTROLLER | Sold 10b5-1 plan | 1,840 | $105.29 | $193,734 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 18 →Other events
AI summary, unreviewedMirum Pharmaceuticals Reports Positive Cohort 2 PROGRESS Results for ATEBRIOZ in Pediatric FOP Patients Aged 6 to <12 Years
Other events
AI summary, unreviewedMirum Pharmaceuticals Phase 3 EXPAND Study of LIVMARLI Meets Primary Endpoint in Ultra-Rare Cholestatic Liver Diseases, Plans sNDA in 1H 2027
Other events
Departure/appointment of directors or officers